| Literature DB >> 23844273 |
Cinzia Signorini1, Claudio De Felice, Thierry Durand, Camille Oger, Jean-Marie Galano, Silvia Leoncini, Alessandra Pecorelli, Giuseppe Valacchi, Lucia Ciccoli, Joussef Hayek.
Abstract
Lipid peroxidation, a process known to induce oxidative damage to key cellular components, has been implicated in several diseases. Following three decades of explorations mainly on in vitro models reproducible in the laboratories, lipid peroxidation has become increasingly relevant for the interpretation of a wide range of pathophysiological mechanisms in the clinical setting. This cumulative effort has led to the identification of several lipid peroxidation end-products meeting the needs of the in vivo evaluation. Among these different molecules, isoprostanes and 4-hydroxy-2-nonenal protein adducts appear to be particularly interesting. This review shows how specific oxidation products, deriving from polyunsaturated fatty acids precursors, are strictly related to the clinical manifestations and the natural history of Rett syndrome, a genetically determined neurodevelopmental pathology, currently classified among the autism spectrum disorders. In our experience, Rett syndrome offers a unique setting for physicians, biologists, and chemists to explore the borders of the lipid mediators concept.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23844273 PMCID: PMC3697420 DOI: 10.1155/2013/343824
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Scheme 1
Figure 1Different classes of isoprostanes (F2-dihomo-IsoPs, F2-IsoPs, and F4-NeuroPs), deriving from polyunsaturated fatty acids precursors (adrenic, arachidonic, and docosahexaenoic acids, resp.), and the 4-hydroxy-2-nonenal protein adducts are strictly related to the clinical manifestations and the natural history of Rett syndrome. The lipid peroxidation events and the disease pathogenic mechanisms are closely interrelated, as demonstrated by the dietary supplementation with ω-3 PUFAs. RTT: Rett syndrome; F2-dihomo-IsoPs: F2-dihomo-isoprostanes; F2-IsoPs: F2-isoprostanes; F4-NeuroPs: F4-neuroprostanes; 4-HNE: 4-hydroxy-2-nonenal; and PUFAs: polyunsaturated fatty acids.